![shutterstock_1221615613 [Converted]-01 (](https://static.wixstatic.com/media/82019c_600022a8e6da4d6383ae9d13827f1f67~mv2.png/v1/crop/x_913,y_5,w_1980,h_1647/fill/w_438,h_364,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/shutterstock_1221615613%20%5BConverted%5D-01%20(.png)
.png){kind=logo}
Science & Applications
RESEARCH PAPERS & SUMMARY
August 2023
The paper showcases the potential of Cannformatics Cannabis-Responsive™ biomarker database to define the mechanism of action (MOA) and therapeutic window for every major cannabinoid.
​
ASD Research Summary
Check out a summary of our research to learn how Cannabis-Responsive™ biomarkers will help physicians, families, and patients with autism take a precision medicine approach to medical cannabis treatments.
![shutterstock_1221615613 [Converted]-01 (](https://static.wixstatic.com/media/82019c_600022a8e6da4d6383ae9d13827f1f67~mv2.png/v1/fill/w_600,h_440,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/shutterstock_1221615613%20%5BConverted%5D-01%20(.png)
March 2022
This paper demonstrates that Cannabis-Responsive biomarkers can provide life science companies and clinicians with new tools for understanding the role of cannabis in maintaining homeostasis of the central nervous system in children with ASD. This study also opens new opportunities to evaluate medical cannabis treatment in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS.
​
December 2021
The paper establishes Cannabis-Responsive biomarkers as a universal measurement of cannabis impact. The study positions medical cannabis as the only peer-reviewed published treatment to show a shift towards the physiological range in children with autism.
​
